OxyContin maker says Mass. lawsuit disorts case facts
Purdue Pharma seeks dismissal
OxyContin maker Purdue Pharma is asking a court to throw out a lawsuit filed by Massachusetts’ attorney general that accuses the company, its owners and top executives of deceiving patients and doctors about the risks of opioids.
In its most expansive response to date, Connecticut-based Purdue argued in a motion filed late Friday that the state makes “sensational and inflammatory allegations” in its bid to hold the company accountable for America’s deadly opioid addiction crisis, and called for the lawsuit to be dismissed “as oversimplified scapegoating based on a distorted account of the facts.”
Jillian Fennimore, a spokeswoman for Democratic Attorney General Maura Healey, said Monday the office would fight the attempt to dismiss the case but did not immediately comment on specific arguments made in the company’s filing.
The lawsuit, filed last year and later amended after the company lost a bid to keep portions of it confidential, claims the company sought to profit off a crisis it helped trigger by telling doctors that OxyContin had a low addiction risk and pushing prescribers to keep patients on the drug longer.
Court documents submitted by the state claimed a member of the Sackler family that owns Purdue Pharma said at a launch party for the opioid painkiller in the 1990s that it would be “followed by a blizzard of prescriptions that will bury the competition.”
The company contends the state is presenting internal company documents in a misleading fashion.
“Recognizing the weakness of its legal theories, (Massachusetts) has resorted to the creation of a sensationalist and distorted narrative that ignores facts and mischaracterizes numerous e-mails and business documents,” the motion states.
Healey’s lawsuit is among more than 1,000 by state and local governments that are pending against drug makers in connection with the opioid crisis that claimed more than 72,000 lives in 2017, according to federal statistics. While most of the suits name multiple defendants, the Massachusetts case focuses solely on Purdue and the Sackler family.
Purdue contends in its latest court filing that many of the marketing and labeling issues raised by Massachusetts around OxyContin have already been addressed by the U.S. Food and Drug Administration and in a 2007 consent agreement that stemmed from an earlier criminal case.
The company also points to the state’s own data and policies in a bid to weaken the basis for the lawsuit, including a recent Department of Public Health report indicating that fentanyl and other illegal drugs — and not prescription painkillers — played a direct role in the vast majority of overdose deaths in Massachusetts last year. Moreover, Purdue noted, state-funded health care programs cover Purdue’s opioid products as “brand preferred” medications.